Clinical Trial Update: A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 results for dronedarone (Multaq) in preventing hospitalization or death in patients with atrial fibrillation or atrial flutter were posted December 23, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• Multaq (dronedarone)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation, Atrial Flutter | Phase 3 | Status: COMPLETED | Results posted: 2009-12-23